ESMO Gastrointestinal Oncology

Additional Metrics

Top Publications

• Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial

  (2023)
  5 Citations

• Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)

  (2023)
  4 Citations

• Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science

  (2023)
  3 Citations

• ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trial

  (2023)
  2 Citations

• VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer

  (2024)
  2 Citations

• SAGA—a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma

  (2024)
  2 Citations

• ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients

  (2024)
  2 Citations

• Immunonutrition supplementation for resectable gastric cancer during standard neoadjuvant chemotherapy of FLOT. A proof-of-concept protocol: I-SUPPLY

  (2024)
  1 Citations

• High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy

  (2024)
  1 Citations

• Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis

  (2023)
  1 Citations